Issue 12 - The Cancer Letter

Vol.

No.

March 22, 2019Mar 22, 2019

DOWNLOAD THE PDF

Cover Story

Texas cancer researchers vying to renew CPRIT beyond its 2023 sunset date

By Claire Dietz and Matthew Bin Han Ong

Conversation with The Cancer Letter

James Willson: CPRIT is money well spent

By Claire Dietz and Matthew Bin Han Ong

Clinical Free Trials & Tribulations

SWOG's 1501 study takes aim at the silo wall between cardiology and oncology

By Justin Floyd

In Brief

Françoise Mornex becomes first female recipient of Heine H. Hansen Award

Gift to UPMC Children's Hospital of Pittsburgh establishes treatment suite for rare early childhood cancer

Funding Opportunities

DoD Prostate Cancer Research Program announces funding opportunities

Clinical Roundup

Breast ultrasound and cancer detection rates increased under new laws

Duke study says genomic testing associated with lower health care costs in high-risk breast cancer patients

Braftovi with Mektovi + Erbitux or panitumumab recommended in advanced BRAF-mutant colorectal

Data from GARNET study indicates robust activity of dostarlimab in endometrial cancer

Drugs & Targets

Tecentriq + chemo gets FDA approval in extensive-stage SCLC

Strata Oncology launches expanded StrataNGS

Oncoceutics and NCI collaborate to develop ONC206

FDA issues warning letters to breast implant manufacturers to deliver on post-approval requirements

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

James Willson: CPRIT is money well spent

SWOG's 1501 study takes aim at the silo wall between cardiology and oncology

In Brief

Françoise Mornex becomes first female recipient of Heine H. Hansen Award

Gift to UPMC Children's Hospital of Pittsburgh establishes treatment suite for rare early childhood cancer

Funding Opportunities

DoD Prostate Cancer Research Program announces funding opportunities

Clinical Roundup

Breast ultrasound and cancer detection rates increased under new laws

Duke study says genomic testing associated with lower health care costs in high-risk breast cancer patients

Braftovi with Mektovi + Erbitux or panitumumab recommended in advanced BRAF-mutant colorectal

Data from GARNET study indicates robust activity of dostarlimab in endometrial cancer

Drugs & Targets

Tecentriq + chemo gets FDA approval in extensive-stage SCLC

Strata Oncology launches expanded StrataNGS

Oncoceutics and NCI collaborate to develop ONC206

FDA issues warning letters to breast implant manufacturers to deliver on post-approval requirements

Recent Issues

Trending Stories

Renew today!

Subscriber content

Login